首页
烟诡
影响力0.00
经验值0.00
粉丝19
化学工艺工程师
来自话题:
求用主成分分析,判别分析 马氏距离处理近红外光谱的教程,? 用SPSS可以直接处理 有相关的 ppt或者视频吗?万分感激!查看更多
在碱液中用泡沫镍用作集流器的问题? 是偏离标准电极电势的那部分电压驱动电化学反应,而不是标准电极电势下发生电化学反应,严格说正负反应一直发生,偏离平衡电压之后正比负多,或者负比正多。所谓标准指的是在标准温度压力,浓度下的电极电势,只 ...查看更多
磷酸铁碳负载前后交流阻抗异常,求高手指点? 重新来一次 看看怎么样啊查看更多
来自话题:
多肽类药物在液相上的分离度和拖尾因子? 加点四氢呋喃,或者换盐的流动相试试,多肽确实不好达到基线分离。查看更多
来自话题:
对照品来源不同。含量差距较大? 同时进行的!先进 USP的对照品溶液后进中检所对照品 ... 对照品双样双针么?平行线咋样?说明书有没有要干燥的要求,说明书中对照品含量多少?说明书中以***计有注意过没??查看更多
来自话题:
求助:最新EP附录2.2.2,谢谢!? 链接: 密码见站内信查看更多
来自话题:
冻干粉针澄清度不合格? 预冻时降温的速率也会影响冰晶尺寸的大小,也会影响产品的质量和溶解速度。 产品冷冻时是否形成玻璃态? 升华温度一般低于共晶点和崩解点温度5-10℃, 可能需要做回热处理。查看更多
来自话题:
求助几个辅料的ep9.0标准? 只查到了3个,解压密码请见“我的短消息”查看更多
来自话题:
以硅球为载体时,转化率为什么下降特别的快? 90度烘干,400度焙烧!查看更多
来自话题:
原料气压缩机的这个水箱有啥作用? 这是水站的水箱吧? 不是,就是两台原料气压缩机中间有一个水箱,不知有啥用? 查看更多
来自话题:
分析非常不靠谱怎么办好呢!? 关键是没有动力去做这些,后面的已经乱七八糟到让人崩溃,前面你还真的有动力去做吗?... 我个人观点:首先我完全理解甚至可以想象这样的情景(我也遇到过),我觉得不说为了课题或者公司,就为了自己,不管您接着干还是换下家假如还做这份工作的话,您得仔仔细细做好样品的取样过程分析,我相信您会发现更多的问题查看更多
来自话题:
有关物质做方法学时是不是已知杂质都需要做线性和回收率? 杂质是否做线性关系是看你的杂质是否在质量标准中控制,你只需要做你在你的质量标准中控制的杂质,也就是说那些没被写进质量标准里的杂质不需要做线性实验,至于那些杂质不列入质量标准中,需要你对工艺的理解程度。 查看更多
来自话题:
进行减压蒸馏时怎么通入氮气保护,画一个装置图,想知道比较具体? 控制进入氮气的量,可以控制抽真空吗查看更多
来自话题:
手性异构体构型转化? 有道理 查看更多
来自话题:
实验仪器去哪儿买? 万能的淘宝 查看更多
来自话题:
关于析晶挂壁问题? 不完全是。我认为溶剂关系很大。换溶剂试试 查看更多
来自话题:
新药研发中对于超限杂质的研究? 这种情况个人是认为必须制备出纯品的。另外有一个情况是,加入这个杂质是由于原料的杂质引入生成的,比如用个什么2,3-二氯苯xx,里面夹带着3,4-二氯苯xx,形成的异构体,在原料这一步就可以精制到0.1以下,这样后面就不用定量控这个杂质了,前提是后面不会新生成。而且一般不会有物质拿不到纯品,真到了个杂质不能稳定存在的地步,或者是容易降解的杂质,那这个杂质不能稳定存在,也就没有必要对它进行定量了,监控降解杂质就行了吧。个人意见。查看更多
来自话题:
生物等效性实验委托? 您好,给您推荐安徽万如医药科技有限公司,公司有多年从事临床研究经验的研究人员组成!欢迎咨询18516275992,邮箱ajun@wr-med.com查看更多
来自话题:
求助:USP40通则<1224>、<1225>、<1226>? :1226? VERIFICATION OF COMPENDIAL PROCEDURES The intent of this general information chapter is to provide general information on the verification of compendial procedures that are being performed for the first time to yield acceptable results utilizing the personnel, equipment, and reagents available. This chapter is not intended for retroactive application to already successfully established laboratory procedures. The chapter Validation of Compendial Procedures ?1225? provides general information on characteristics that should be considered for various test categories and on the documentation that should accompany analytical procedures submitted for inclusion in USP–NF. Verification consists of assessing selected analytical performance characteristics, such as those that are described in chapter ?1225?, to generate appropriate, relevant data rather than repeating the validation process. Users of compendial analytical procedures are not required to validate these procedures when first used in their laboratories, but documented evidence of suitability should be established under actual conditions of use. In the United States, this requirement is established in 21 CFR 211.194(a)(2) of the current Good Manufacturing Practice regulations, which states that the “suitability of all testing methods used shall be verified under actual conditions of use.” Verification of microbiological procedures is not covered in this chapter because it is covered in USP general test chapters Antimicrobial Effectiveness Testing ?51?, Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests ?61?, Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms ?62?, Sterility Tests ?71?, and in general information chapter Validation of Microbial Recovery from Pharmacopeial Articles ?1227?. VERIFICATION PROCESS The verification process for compendial test procedures is the assessment of whether the procedure can be used for its intended purpose, under the actual conditions of use for a specified drug substance and/or drug product matrix. Users should have the appropriate experience, knowledge, and training to understand and be able to perform the compendial procedures as written. Verification should be conducted by the user such that the results will provide confidence that the compendial procedure will perform suitably as intended. If the verification of the compendial procedure is not successful, and assistance from USP staff has not resolved the problem, it may be concluded that the procedure may not be suitable for use with the article being tested in that laboratory. It may then be necessary to develop and validate an alternate procedure as allowed in the General Notices. The alternate procedure may be submitted to USP, along with the appropriate data, to support a proposal for inclusion or replacement of the current compendial procedure. VERIFICATION REQUIREMENTS Verification requirements should be based on an assessment of the complexity of both the procedure and the material to which the procedure is applied. Although complete revalidation of a compendial method is not required to verify the suitability of a procedure under actual conditions of use, some of the analytical performance characteristics listed in chapter ?1225?, Table 2, may be used for the verification process. Only those characteristics that are considered to be appropriate for the verification of the particular procedure need to be evaluated. The process of assessing the suitability of a compendial analytical test procedure under the conditions of actual use may or may not require actual laboratory performance of each analytical performance characteristic. The degree and extent of the verification process may depend on the level of training and experience of the user, on the type of procedure and its associated equipment or instrumentation, on the specific procedural steps, and on which article(s) are being tested. Verification should assess whether the compendial procedure is suitable for the drug substance and/or the drug product matrix, taking into account the drug substance's synthetic route, the method of manufacture for the drug product, or both, if applicable. Verification should include an assessment of elements such as the effect of the matrix on the recovery of impurities and drug substances from the drug product matrix, as well as the suitability of chromatographic conditions and column, the appropriateness of detector signal response, etc. As an example, an assessment of specificity is a key parameter in verifying that a compendial procedure is suitable for use in assaying drug substances and drug products. For instance, acceptable specificity for a chromatographic method may be verified by conformance with system suitability resolution requirements (if specified in the procedure). However, drug substances from different suppliers may have different impurity profiles that are not addressed by the compendial test procedure. Similarly, the excipients in a drug product can vary widely among manufacturers and may have the potential to directly interfere with the procedure or cause the formation of impurities that are not addressed by the compendial procedure. In addition, drug products containing different excipients, antioxidants, buffers, or container extractives may affect the recovery of the drug substance from the matrix. In these cases, a more thorough assessment of the matrix effects may be required to demonstrate suitability of the procedure for the particular drug substance or product. Other analytical performance characteristics such as an assessment of the limit of detection or quantitation and precision for impurities procedures may be useful to demonstrate the suitability of the compendial procedure under actual conditions of use. Verification is not required for basic compendial test procedures that are routinely performed unless there is an indication that the compendial procedure is not appropriate for the article under test. Examples of basic compendial procedures include, but are not limited to, loss on drying, residue on ignition, various wet chemical procedures such as acid value, and simple instrumental determinations such as pH measurements. However, for the application of already established routine procedures to compendial articles tested for the first time, it is recommended that consideration be given to any new or different sample handling or solution preparation requirements. Auxiliary Information— Please check for your question in the FAQs before contacting USP. Topic/Question Contact Expert Committee General Chapter Horacio N. Pappa, Ph.D. Director (301) 816-8319 (GCCA2015) General Chapters-Chemical Analysis 2015 USP40–NF35 Page 1786 Previously Appeared In: Pharmacopeial Forum: Volume No 查看更多
来自话题:
液相化合物出峰的峰型? 加千分之一三氟乙酸 查看更多
简介
职业:恒河材料科技股份有限公司 - 化学工艺工程师
学校:西华师范大学 - 化学化工学院
地区:山东省
个人简介:真实是人生的命脉,是一切价值的根基。查看更多
已连续签到天,累积获取个能量值
  • 第1天
  • 第2天
  • 第3天
  • 第4天
  • 第5天
  • 第6天
  • 第7天
 
这是一条消息提示
 
提醒
您好,您当前被封禁天,这天内您将不能登陆盖德问答,离解封时间还有
我已了解
提醒
提问需要5个能量值,您当前能量值为,请完成任务提升能量值
去查看任务